Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 54,938 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Glioblastoma
Interventions: Hypofractionated radiotherapy, Temozolomide; Radiation · Drug
Lead sponsor: University of Louisville; Other
Eligibility: 70 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Type 2 Diabetes Mellitus
Interventions: tirzepatide, Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Mobile, Alabama • Anaheim, California • Fresno, California + 30 more

Conditions: Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Mixed Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Ovarian Neoplasm, Malignant Ovarian Serous Tumor, Malignant Ovarian Transitional Cell Tumor, Ovarian Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 131
States / cities: Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 99 more

Conditions: Thyroid Gland Medullary Carcinoma
Interventions: Decision Aid, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cerebrovascular Accident
Interventions: LARA, Standard; Device · Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acute Respiratory Failure, Mechanical Ventilation, Life-Supporting Treatments, Communication, Decision Making, Critical Care, Palliative Care
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 7,818 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania • Madison, Wisconsin

Conditions: Hyponatremia, SIADH
Interventions: Tolvaptan; Drug
Lead sponsor: Polderman, Kees, H., MD, PhD; Individual
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Pain, Surgery
Interventions: Prescription by surgical team, Recommendation by surgical team; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Invasive Breast Cancer, Post-mastectomy
Interventions: Radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: Video Education Program; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Interventions: Autologous HB-adMSCs; Drug
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Rheumatoid Arthritis
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: Ronald J. Rapoport, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fall River, Massachusetts

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Multiple Sclerosis
Interventions: N-acetyl Cysteine; Dietary Supplement
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Any Advanced Solid Tumors
Interventions: Sarilumab, ICI Therapy; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Arthroplasty, Replacement, Knee
Interventions: Vanguard Knee System with Signature Knee Guide, Vanguard Knee System with conventional Instruments; Procedure
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
Interventions: Pimavanserin; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 50 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dementia, Alzheimer's Disease
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 14
States / cities: Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more

Conditions: Major Depression
Interventions: Conventional cognitive behavioral therapy, Religious cognitive behavioral therapy; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Glendale, California • Durham, North Carolina

Conditions: Melanoma (Skin)
Interventions: boron neutron capture therapy; Radiation
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions: Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS); Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Stage IV Lung Adenocarcinoma
Interventions: Certolizumab, cisplatin, pemetrexed; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more

Conditions: Aortic Valve Stenosis
Interventions: TAVR with CENTERA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more

Search by objective public record fields.

A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

Efficacy Study of the LARA Wheelchair System for Subacute Stroke Patients

A Study of Communication Between Clinicians, Patients, and Families in the Intensive Care Unit (ICU)

Tolvaptan for Patients With Acute Neurological Injuries

Prescribing Vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients with Postoperative Pain:

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer

Video Education to Improve Rural Cancer Care Delivery

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer

Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

Signature Personalised Patient Care System With the Vanguard Knee System Study

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Cognitive Behavioral Treatments for Depression in Chronic Illness

Boron Neutron Capture Therapy in Treating Patients With Melanoma

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis